Latest Conference Articles

An overview of the potential treatment strategies for patients were presented at the 2024 World Conference on Lung Cancer.

Promising abstracts surrounding DLL3 targeting for patients with lung and neuroendocrine cancer were presented at WCLC 2024.

As of May 2024, follow-up and exploratory analyses of MARIPOSA show improvements in outcomes for patients with EGRF-mutated non–small cell lung cancer (NSCLC).

In a session at the 2024 World Conference on Lung Cancer, presenters highlight the most significant developments in local therapy for metastatic non–small cell lung cancer and advanced disease.

Highlights from multiple trials investigating novel treatments for mNSCLC were presented at 2024 World Conference on Lung Cancer.

Mark Fendrick, MD, speaks about the importance of improving financial toxicity for patients while optimizing their outcomes.

Presentations highlighted the potential of tarlatamab in treating solid tumor cancers.

Lalan Wilfong, MD, discusses the road to value-based care and payment reform in cancer care.

Datopotamab deruxtecan was effective in patients with TROP2-QCS biomarker-positive tumors for non–small cell lung cancer

Lazertinib with amivantamab was found to be similar in efficacy to osimertinib in the MARIPOSA study.

Alessandra Ferrajoli, MD, discusses the importance of renal function for BCL2 inhibitors to avoid tumor lysis syndrome and cardiovascular history for BTK inhibitors to mitigate arrhythmia risks.

Reid Merryman, MD, discusses the potential for minimal residual disease (MRD) to inform treatment decisions, identify lymphoma subgroups, and infer gene expression.

Disease-related factors include several prognostic scoring systems, such as DIPSS, whereas patient-related factors involve age, comorbidities, spleen size, and anemia.

Optimizing outcomes for patients with chronic myeloid leukemia (CML) requires personalized treatment, adaptive dosing, and precise genetic insights.

Stefan Barta, MD, MS, MRCPCUK, discusses the potential role of biomarkers in predicting treatment outcomes, the emerging use of CAR T-cell therapy, and the benefits and challenges of combination therapies in managing T-cell lymphoma.

Sonali Smith, MD, discusses T-cell–directed therapies for indolent B-cell lymphoma, focusing on their efficacy, FDA-approved treatments, and treatment challenges, such as managing cytokine release syndrome.

Rather than “trial-and-erroring” transplants for patients, experts should instead select transplants that are precise, personalized, and predictable.

Clinical improvements for patients with diabetes seen in a collaboration between the University of North Carolina and Blue Cross and Blue Shield of North Carolina.

In an interview with Pharmacy Times, Jasmine Perry describes her idea of an effective health care delivery model and why research can have a huge impact at the policy level.

Drawing on years of experience, Rina Shah explains how sustainable care models are essential for a thriving pharmaceutical industry.

In an interview with Pharmacy Times, Jon Easter discusses the need for pharmacy to align as a profession to achieve policy and research goals.

President of NACDS, Steve Anderson, discusses how the events at Total Store Expo reflect on the association's goals of innovation and a focus on public policy.

Sara Roszak recounts the Annual NACDS Foundation Dinner and their role in implementing research at the clinical level.

Jasmine Perry discusses the More Than a Script program in an interview with Pharmacy Times.

In a session at NACDS Total Store Expo, experts spoke to the success of value-based care models in the pharmaceutical industry.

Steve Anderson, president and CEO of the National Association of Chain Drug Stores (NACDS), discusses memorable moments from this year's NACDS Total Store Expo.

Sara Roszak discusses her role as president of the NACDS Foundation.

Scott Biggs and Doug Long explain current trends in the pharmaceutical industry and the importance of ensuring pharmacists are informed.